453565-76-9

Basic information

• Product Name: methyl 3-cyano-5-hydroxybenzoate
• Synonyms: methyl 3-cyano-5-hydroxybenzoate
• CAS NO: 453565-76-9
• Molecular Formula: C₉H₇NO₃
• Molecular Weight: 177.15678
• Mol File: 453565-76-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-cyano-5-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-cyano-5-hydroxybenzoate(453565-76-9)
• EPA Substance Registry System: methyl 3-cyano-5-hydroxybenzoate(453565-76-9)

Safety Data

• Hazardous Substances Data: 453565-76-9(Hazardous Substances Data)

Upstream product

• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 67-56-1 methanol 
• 1163141-57-8 3-cyano-5-hydroxy-benzoic acid 
• 453565-69-0 methyl 3-(allyloxy)-5-cyanobenzoate 

Downstream Products

• 1163141-58-9 methyl 3-cyano-5-(2,2,2-trifluoroethoxy)benzoate 
• 1163141-62-5 methyl 3-cyano-5-(2-fluoroethoxy)benzoate 
• 1163141-65-8 methyl 3-cyano-5-(cyclopentyloxy)benzoate 
• 453565-70-3 3-cyano-5-propoxybenzoic acid 
• 453565-85-0 3-cyano-5-ethoxybenzoic acid 
• 453565-86-1 methyl 3-cyano-5-ethoxybenzoate 
• 453565-77-0 methyl 3-cyano-5-(2-methoxyethoxy) benzoate 

Relevant articles and documents

FLUOROPHENYL PYRAZOL COMPOUNDS

The present invention provides a compound of the Formula (I), wherein X is selected from the group consisting of (II); R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 and (III); or a pharmaceutically acceptable salt thereof.

FLUOROPHENYL PYRAZOL COMPOUNDS

The present invention provides a compound of the Formula: wherein X is selected from the group consisting of, R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 or a pharmaceutically acceptable salt thereof.

TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.